Tyr Pharma stock rated Hold after mixed trial results for efzofitimod; promising secondary data, but there remains uncertainty. Find out why ATYR is a Hold.

Audrey was in seventh grade when her bones started breaking: eight in total, over six months. Some of them broke dramatically ...

Good morning, ladies and gentlemen, and welcome to aTyr Pharma conference call to review the top line results for the Phase III EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. [Operator ...

A large-scale international study led by the University of Liverpool and funded by the Epilepsy Research Institute UK has ...

Breast cancer is already costing the UK economy between £3.2bn and £3.5bn - but could rise to £4.2bn in the next 25 years ...

Women in India are more likely to get cancer. Men are more likely to die from it. The paradox, revealed in a study of the country's latest cancer registry, tells a story at once simple and confounding ...

J. Tyler Davidson of the Department of Forensic Science at Sam Houston State University (Huntsville, Texas) used liquid ...

Imperial College London's Department of Infectious Disease Epidemiology reports a model-predictive control approach that ...

A coalition of drug policy reform and civil rights organizations sent letter urging members of the U.S. House of ...

The Trump administration’s plan to torpedo air pollution limits and cancer prevention programs while ripping away health care ...